Considering that KPNA2 is overexpressed in lung adenocarcinoma and squamous cell carcinoma, which is the most common type of NSCLC that involves a deregulated PI3K/AKT/mTOR pathway [6, 45-48], we proposed that KPNA2 would be a potentially predictive biomarker of responsiveness to PI3K/AKT/mTOR-targeted therapy in NSCLC. This evidence concerns the gene KPNA2 and squamous cell carcinoma.